{
    "id": 14747,
    "fullName": "PIK3R1 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PIK3R1 mutant indicates an unspecified mutation in the PIK3R1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 5295,
        "geneSymbol": "PIK3R1",
        "terms": [
            "PIK3R1",
            "AGM7",
            "GRB1",
            "IMD36",
            "p85",
            "p85-ALPHA"
        ]
    },
    "variant": "mutant",
    "createDate": "12/04/2015",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6404,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study of a Phase II trial, mutation status of PIK3R1 was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228).",
            "molecularProfile": {
                "id": 15004,
                "profileName": "PIK3R1 mutant"
            },
            "therapy": {
                "id": 936,
                "therapyName": "Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5557,
                    "pubMedId": 27016228,
                    "title": "Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27016228"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3720,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, one patient with PIK3R1 and PTEN mutant endometrial cancer had a durable partial response to LY3023414 (J Clin Oncol 33, 2015 (suppl; abstr 11075)).",
            "molecularProfile": {
                "id": 15005,
                "profileName": "PIK3R1 mut PTEN mut"
            },
            "therapy": {
                "id": 1069,
                "therapyName": "LY3023414",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4035,
                    "pubMedId": null,
                    "title": "A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.",
                    "url": "http://meetinglibrary.asco.org/content/144556-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10284,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an endometrial cell line xenograft model harboring an FGFR2 activating mutation, a PIK3R1 mutation, and PTEN loss was sensitive to Miransertib (ARQ092), demonstrating inhibition of tumor growth (PMID: 26469692).",
            "molecularProfile": {
                "id": 27340,
                "profileName": "FGFR2 act mut PIK3R1 mut PTEN loss"
            },
            "therapy": {
                "id": 635,
                "therapyName": "Miransertib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8234,
                    "pubMedId": 26469692,
                    "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10367,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line harboring a PIK3CA activating mutation, PIK3R1 mutation, and PTEN wild-type demonstrated sensitivity to Torkinib (PP242) in culture, resulting in decreased cell viability (PMID: 21358673).",
            "molecularProfile": {
                "id": 27385,
                "profileName": "PIK3CA act mut PIK3R1 mut PTEN wild-type"
            },
            "therapy": {
                "id": 2240,
                "therapyName": "Torkinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3638,
                    "pubMedId": 21358673,
                    "title": "PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21358673"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 15004,
            "profileName": "PIK3R1 mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 15005,
            "profileName": "PIK3R1 mut PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27340,
            "profileName": "FGFR2 act mut PIK3R1 mut PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27385,
            "profileName": "PIK3CA act mut PIK3R1 mut PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35152,
            "profileName": "ERBB2 mut PIK3R1 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}